The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients

Hemoglobin

Volumn 36, Issue 4, 2012, Pages 371-380

  Banan, Mehdi ^a   Bayat, Hadi ^a   Azarkeivan, Azita ^b,c   Mohammadparast, Saeid ^a   Kamali, Koorosh ^d   Farashi, Samaneh ^a   Bayat, Nooshin ^e   Khani, Masumeh Hadavand ^c   Neishabury, Maryam ^a   Najmabadi, Hossein ^a,e  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^b IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^c Adult thalassemia Clinic   (Iran)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

^e Kariminejad Najmabadi Pathology and Genetics Center   (Iran)

Author keywords

Thalassemia ( thal); BCL11A Single nucleotide polymorphism (SNP); Hydroxyurea (HU); XmnI Polymorphism

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA; SPACER DNA;

ADULT; ALLELE; ARTICLE; BCL11A GENE; BETA THALASSEMIA; BLOOD TRANSFUSION; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC MARKER; GENOTYPE; HBS1L MYB GENE; HUMAN; INTRON; IRAN; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; XMNI GENE;

ADULT; ANTISICKLING AGENTS; BETA-THALASSEMIA; BLOOD TRANSFUSION; FEMALE; FETAL HEMOGLOBIN; GENE FREQUENCY; GENOTYPE; HUMANS; HYDROXYUREA; IRAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862870642     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2012.691147     Document Type: Article

References (35)

1. Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol. 2009;88(6):505-528.
2. Saunthararajah Y, Atweh GF. Induction of fetal hemoglobin in the treatment of sickle cell disease and β thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, Eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Management, 2nd ed.New York:Cambridge University Press. 2009:745-754.
3. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148(12):939-955.
4. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95(11):3589-3593.
5. Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 2007;7(6):386-394.
6. Kumkhaek C, Taylor JG, Zhu J, Hoppe C, Kato GJ, Rodgers GP. Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. Br J Haematol. 2008;141(2):254-259.
7. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. Proc Natl Acad Sci USA. 2008;105(5):1620-1625.
8. Lettre G, Sankaran VG, Bezerra MAC, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA. 2008;105(33):11869-11874.
9. Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet. 2010;42(12):1049-1051.
10. Sedgewick AE, Timofeev N, Sebastiani P, et al. BCL11A is a major Hb F quantitative trait locus in three different populations with β-hemoglobinopathies. Blood Cells Mol Dis. 2008;41(3):255-258.
11. Gγ polymorphism influences Hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 β-thalassemia intermedia patients. Blood Cells Mol Dis. 2010;45(2):124-127.
12. Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol. 2009;145(4):455-467.
13. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839-1842.
14. Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature. 2009;460(7259):1093-1097.
15. Jiang J, Best S, Menzel S, et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood. 2006;108(3):1077-1083.
16. Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum Mol Genet. 2009;18(R2):R216-R223.
17. Bradai M, Pissard S, Abad MT, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47(10):1830-1836.
18. Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients. Haematologica. 2004;89(10):1172-1178.
19. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening. Ann Hematol. 2004;83(7):430-433.
20. Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann Hematol. 2005;84(7):441-446.
21. Singer ST, Kuypers FA, Olivieri NF, et al. Fetal haemoglobin augmentation in E/β0 thalassaemia: clinical and haematological outcome. Br J Haematol. 2005;131(3):378-388.
22. Galanello R, Sanna S, Perseu L, et al. Amelioration of Sardinian β0 thalassemia by genetic modifiers. Blood. 2009;114(18):3935-3937.
23. Badens C, Joly P, Agouti I, et al. Variants in genetic modifiers of β-thalassemia can help to predict the major or intermedia type of the disease. Haematologica. 2011;96(11):1712-1714.
24. Danjou F, Anni F, Galanello R. β-Thalassemia: from genotype to phenotype. Haematologica. 2011; 96(11):1573-1575.
25. Danjou F, Anni F, Perseu L, et al. Genetic modifiers of β-thalassemia and clinical severity as assessed by age at first transfusion. Haematologica 2012 [Epub ahead of print].
26. Italia KY, Jijina FJ, Merchant R, et al. Response to hydroxyurea in β thalassemia major and intermedia: experience in western India. Clin Chim Acta. 2009;407(1-2):10-15.
27. Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in β-thalassemia. Am J Hematol. 2008;83(5):366-370.
28. Vasavda N, Woodley C, Allman M, et al. Effects of co-existing α-thalassaemia in sickle cell disease on hydroxycarbamide therapy and circulating nucleic acids. Br J Haematol. 2011;157(2):249-252.
29. Hadavi V, Taromchi AH, Malekpour M, et al. Elucidating the spectrum of α-thalassemia mutations in Iran. Haematologica. 2007;92(7):992-993.
30. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
31. Ye S, Dhillon S, Ke X, Collins AR, Day I.N.M. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001;29(17):e88-e88.
32. Thein SL, Wood WG. The molecular basis of β thalassemia, δβ thalassemia, and hereditary persistence of fetal hemoglobin. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, Eds. Disorders of Hemoglobin, 2nd ed. New York: Cambridge University Press. 2009:323-356.
33. Karimi M, Yarmohammadi H, Farjadian S, et al. β-Thalassemia intermedia from southern Iran: IVS-II-1 (G→A) is the prevalent thalassemia intermedia allele. Hemoglobin. 2002;26(2):147-154.
34. Arab A, Karimipoor M, Rajabi A, Hamid M, Arjmandi S, Zeinali S. Molecular characterization of β-thalassemia intermedia: a report from Iran. Mol Biol Rep. 2010;38(7):4321-4326.
35. Lewis CM. Genetic association studies: design, analysis and interpretation. Brief Bioinform. 2002; 3(2):146-153.